BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose. Copyright 2008 Massachusetts Medical Society.
BACKGROUND:Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose. Copyright 2008 Massachusetts Medical Society.
Authors: Chihiro Koike; Monica Uddin; Derek E Wildman; Edward A Gray; Massimo Trucco; Thomas E Starzl; Morris Goodman Journal: Proc Natl Acad Sci U S A Date: 2006-12-28 Impact factor: 11.205
Authors: Justus Adédoyin; Hans Grönlund; Hans Oman; S G O Johansson; Marianne van Hage Journal: J Allergy Clin Immunol Date: 2007-03 Impact factor: 10.793
Authors: Sarah A Lewis; Scott T Weiss; Thomas A E Platts-Mills; Harriet Burge; Diane R Gold Journal: Am J Respir Crit Care Med Date: 2002-04-01 Impact factor: 21.405
Authors: Thomas A E Platts-Mills; Shama M Satinover; Lisa Naccara; Augusto A Litonjua; Wanda Phipatanakul; Melody C Carter; Peter W Heymann; Judith A Woodfolk; Edward J Peters; Diane R Gold Journal: J Allergy Clin Immunol Date: 2007-09-04 Impact factor: 10.793
Authors: Bert H O'Neil; Robert Allen; David R Spigel; Thomas E Stinchcombe; Dominic T Moore; Jordan D Berlin; Richard M Goldberg Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245
Authors: Yoann Pointreau; Scott P Commins; Gilles Calais; Hervé Watier; Thomas A E Platts-Mills Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown Journal: Br J Clin Pharmacol Date: 2014-07 Impact factor: 4.335
Authors: Scott P Commins; Shama M Satinover; Jacob Hosen; Jonathan Mozena; Larry Borish; Barrett D Lewis; Judith A Woodfolk; Thomas A E Platts-Mills Journal: J Allergy Clin Immunol Date: 2008-12-13 Impact factor: 10.793